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Abstract
Severe invasive group A streptococcal diseases have re-emerged during the past 10–20 years. In order to provide a better insight into the
current epidemiological situation in France, we analysed the questionnaires regarding all invasive strains received at the National Reference
Center for Streptococci (CNR-Strep) between 2006 and 2010 from patients aged ‡18 and characterized them by emm typing, spe gene
detection and antibiotic resistance. Among the 1542 invasive GAS strains studied, 78% (n = 1206) were from blood cultures, and a strep-
tococcal toxic shock syndrome (STSS) was described in 22% (n = 340) of cases, mainly associated with necrotizing fasciitis (NF) and pleu-
ro-pulmonary infections (p <0.001). The in-hospital fatality rate was 15%. A total of 83 different emm types were recovered but the three
predominant emm types, representing almost 60% of the isolates, were emm1 (24%), emm28 (17%) and emm89 (15%). The preponderance
of each emm type varied according to the year, with a significant constant increase of emm28 strains, whereas emm1 strains, representing
approximately 32% of GAS invasive isolates in 2007 and 2008, dropped to <15% in 2010 (p <0.001). The distribution of phage-associated
superantigen genes (speA, speC and ssa) was linked to certain emm types. Between 2006 and 2010, the percentage that was macrolide-
resistant decreased from 11% to 5%, confirming the trend observed in 2007. Fortunately, emm1 strains associated with the most life-
threatening clinical manifestations remain susceptible to all anti-streptococcal antibiotics.
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Introduction
Streptococcus pyogenes or group A streptococcus (GAS) is a
human pathogen with a worldwide distribution [1]. Most
often it causes mild superficial infections of the skin, such as
impetigo, or of the upper respiratory tract, such as pharyngi-
tis. However, bacteraemia and necrotizing fasciitis (NF)
associated or not with streptococcal toxic shock syndrome
(STSS) are life-threatening GAS infections. An increase of
invasive GAS infections during the 1980s has been noticed
worldwide [1]. In France, between 2000 and 2009, the inci-
dence of GAS bacteraemia (i.e. positive blood and cerebro-
spinal fluid cultures) increased from 1.5 to 2.6 cases per
100 000 population according to the report of the Epibac
national hospital-based laboratory network (http://
www.cdc.gov/ncidod/biotech/strep/strepblast.htm). In 2007 in
France, the overall incidence of invasive GAS infections,
including deep infections, such as pneumonia and postpartum
endometritis, and STSS without positive blood cultures, was
estimated to be 3.1 (95% CI, 2.9–3.2) cases per 100 000
population [2]. This trend seems to be stable as incidence
rates of invasive GAS infections in 2008 and 2009 were 2.4
and 2.6 per 100 000 population, respectively.
Several important virulence factors involved in GAS patho-
genicity have been described, including the M protein and
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the exotoxins [3]. The M protein is a fimbrial surface protein
encoded by the emm gene and more than 160 different M
protein gene sequence types (emm types) have been
described. Determination of the emm type is mandatory for
epidemiological investigations of GAS infections [4,5]. Strep-
tococcal pyrogenic exotoxins SpeA, SpeC, SpeG to SpeM,
streptococcal superantigen A (SSA), and streptococcal mito-
genic exotoxin Z (SmeZ) have been identified as superanti-
gens (SA) [6,7]. The proteins SpeB and SpeF, initially
described as toxins, were shown to be a cysteine protease
and a DNase, respectively. Usually, isolates of the same emm
type share a similar SA profile but variants differing by the
presence or absence of SA may occur [8].
Group A streptococcus strains remain susceptible to b-
lactams, which is the treatment of choice for GAS infections.
However, in patients with b-lactam allergy, macrolides and
lincosamides are first-line alternative therapeutics. Moreover,
clindamycin is used in association with penicillin to treat
STSS to reduce, as a protein synthesis inhibitor, the synthesis
of virulence factors [9]. In recent years, macrolide- and linco-
samide-resistant GAS strains have gradually spread [10–13],
in particular among certain emm types [14,15].
The aim of this study was to provide a better insight into
the current epidemiological situation regarding adult invasive
GAS infections in France. We analysed the questionnaires
and characterized all invasive strains received at the National
Reference Center for Streptococci (CNR-Strep) between
2006 and 2010 from patients aged 18 years and over, by
emm typing, SA gene detection and antibiotic resistance.
Methods
Case definition
Group A streptococcus invasive infection was defined as the
isolation of bacteria from a usually sterile site (e.g. blood,
cerebrospinal fluid, bone or joint fluid), or from samples
obtained from a non-sterile site in combination with clinical
signs of NF or STSS. STSS was defined according to the defi-
nitions of the US Working Group on Severe Streptococcal
Infections [16]. Bacteraemia was considered to be without
focus when no focal symptoms could be identified. In this
report, all non-redundant invasive GAS strains isolated from
patients ‡18 years, between January 2006 and December
2010 and sent to the CNR-Strep, were studied.
Collection of clinical data and strains
The French national reference centre for streptococci
(CNR-Strep) collects, prospectively, GAS strains isolated
from invasive infections from a stable network of 232 labora-
tories located throughout the 22 French administrative
regions. Forty-three (18%) laboratories belonged to univer-
sity hospitals, 157 (68%) were located in general hospitals,
and the remaining 32 (14%) were private laboratories. Clini-
cal characteristics were obtained from questionnaires sent
on a voluntary basis with invasive isolates. Data collected
included sex, date of birth, date and origin of the sample,
geographical area and clinical manifestations. Strains were
stored in 2% glycerol Todd Hewitt broth at )80C.
Strains identification
Group A streptococcus isolates were confirmed to be S. py-
ogenes using morphological and growth characteristics,
including b haemolysis on sheep blood agar, production of
pyrrolydonyl arylamidase, and grouping of carbohydrate with
Lancefield group A specific antigen.
emm sequence typing
The emm sequence type was determined by sequencing
the variable 5¢-end of the emm gene and comparing
sequences with the database of the Center for Disease
Control and Prevention (http://www.cdc.gov/ncidod/biotech/
strep/doc.htm).
Superantigen detection
All the strains were tested by a multiplex PCR method for
the presence of genes encoding the toxins or superantigens
SpeA, SpeB, SpeC and Ssa [17,18].
Antibiotic susceptibility testing
Antibiotic susceptibility to penicillin G, amoxicillin, erythro-
mycin, clindamycin, tetracycline, gentamicin, levofloxacin and
vancomycin was determined by the disk diffusion method on
Mueller–Hinton agar with 5% sheep blood according to CAS-
FM guidelines (http://www.sfm.asso.fr). Macrolides and tetra-
cycline-resistant genes were detected by multiplex PCR as
described [19].
Statistical analysis
The chi-square test for trend was used and p <0.05 was con-
sidered significant for all tests.
Results
Number of cases and demographic characteristics
From January 2006 to December 2010, 1542 cases of inva-
sive GAS infections were reported to the CNR-Strep by the
microbiologists of the 232 laboratories located throughout
the 22 French administrative regions (range by year, 183–
CMI Plainvert et al. Group A streptococcus adult invasive infections 703
ª2011 The Authors
Clinical Microbiology and Infection ª2011 European Society of Clinical Microbiology and Infectious Diseases, CMI, 18, 702–710
459) (Fig. 1). An over-representation of cases in 2007 was
linked to the French national survey performed in collabora-
tion with the Institut National de Veille Sanitaire (InVS) [2].
The number of GAS strains collected by region was corre-
lated with the population density. Therefore two regions, Ile
de France and Rhoˆne-Alpes, provided 18% and 12% of GAS
isolates, respectively (data not shown). Seasonal patterns of
invasive GAS infections were observed but varied depending
on the year. However, for all years, cases gradually increased
from the end of October to April (Fig. 1b). The median age
was 60.3 years (range 18–103) and 52.4% were female
(Fig. 1). The number of cases increased with the age of the
patients. Among those between 40 and 79 years old, cases
were more frequent in men than in women (p <.0001).
Clinical manifestations
Among the 1542 invasive GAS infections included in the
study, 1206 (78.2%) cases have a documented bacteraemia.
Various clinical manifestations were reported (Table 1). Skin
or soft tissue infections were the most frequent, accounting
for 43.7% of the cases. NF was reported in 21.8% of cases,
accounting for 50% of skin and soft tissue infections, and was
2-fold more frequent in men between 30 and 59 years old
than in women (p <0.01). The frequency of other strepto-
coccal diseases was as follows: gynaeco-obstetrical sepsis,
8.9%; pleuro-pulmonary infections, 8.8%; osteoarticular, 6.9%;
and other clinical manifestations such as intra-abdominal
infections, upper respiratory tract or central nervous system
infections, <5% of cases. Bacteraemia without focal symp-
toms accounted for 391 (25.4%) of the cases. Gynaeco-
obstetrical sepsis represented 53.2% of cases in women of
childbearing age (18–39 years, n = 218). An STSS was
described in 22% (n = 340) of cases. It was, respectively, 3-
and 1.9-fold more frequently observed in cases of NF and
pleuro-pulmonary infections (p <0.001) than in other clinical
manifestations. STSS was more frequently reported in per-
sons aged 50–69 years (29.6% vs. 19.2%, p <0.001). The
in-hospital fatality rate, available in 231 cases, was 15%; it
reached 18.1% of NF and 44.9% of STSS. The lowest fatality
rate (<1%) was observed in young women with postpartum
sepsis.
emm sequence types and streptococcal diseases
A total of 83 different emm sequence types were identified.
All strains belonged to an already described emm type. Three
predominant emm types, namely emm1 (24%), emm28 (17%)
and emm89 (15%), accounted for 56% of all isolates over the
5-year period. The distribution of emm types varied accord-
ing to the year considered (Fig. 2a). A significant increase of
emm28 strains was observed from 2006 (14%) to 2010 (25%,
p <.01). A similar trend, although not significant, was
observed for emm3 strains during the 5-year period (6% in
2006 to 8.5% in 2010). Consequently, emm1 strains, which
represented approximately 32% of GAS invasive isolates in
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FIG. 1. Distribution of adult invasive GAS strains according to sex, age and year of isolation (a) and to the month of the year (b).
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2007 and 2008, dropped to <15% in 2010 (p <0.001). emm1
strains were recovered from 32% (n = 108/337) of NF and
37.9% of STSS (n = 129/340) (Table 2) cases. Three other
major genotypes within STSS cases were emm3 (n = 35/340),
emm89 (n = 35/340) and emm28 (n = 34/340). Each of them
was, respectively, responsible for <11% of STSS cases.
Among skin and soft tissue infections, emm1 strains were
responsible for most of the NF cases (p <0.001) whereas
erysipelas were mainly caused by emm28 strains (p <0.001).
Moreover, emm28 strains seemed to be associated with sep-
tic arthritis and gynaeco-obstetrical infections (p <0.01 and
p <0.001, respectively). GAS strains isolated from pulmonary
infections were predominantly emm1 (p <0.001). emm87
strains were identified mostly in patients aged 50–59 years
old, whereas emm22 were predominantly found in those
under 30 years (p <0.001) unless there was a particular link
with any clinical manifestation.
Superantigen gene patterns and emm types
speB, encoding the chromosomal cysteine protease, was
detected in all strains. speA carried by prophages was detected
among 492 strains, primarily in emm1 (n = 365; 74.2%) and
emm3 (n = 79; 16%) strains (p <0.001) (Fig. 2b). The remain-
der speA-positive isolates (48; 9.8%) included emm6, emm11,
emm22, emm28, emm77, emm82, emm83, emm87 and emm89
strains. However, speA was not detected in emm2, emm4,
emm12, emm44, emm64, emm75 or emm83 strains. speC was
detected in 15 out of the 17 most prevalent emm types and in
more than 90% of emm2, emm4, emm6, emm11 and emm28
strains. Ten different emm types were positive for ssa, includ-
ing more than 70% of emm3, emm4, emm22 and emm87 strains
(p <0.001). Conversely, ssa was never detected in emm2,
emm6, emm11, emm64, emm77, emm82 or emm83 types. STSS
occurred more frequently in GAS strains harbouring speA or
speC SA genes (p <0.001) than ssa.
(a)
(b)
FIG. 2. Molecular characterization of GAS isolated from invasive infections in adults, France 2006–2010. (a) Distribution of the top 17 emm
types, for which more than ‡10 strains were isolated; ‘others’ designates all strains belonging to rare emm types (£9 strains): emm5, emm8,
emm9, emm18, emm25, emm27G, emm29, emm32, emm33, emm42, emm43, emm46, emm49, emm50, emm53, emm56, emm58, emm59, emm60,
emm61, emm63, emm65, emm68, emm69, emm71, emm73, emm74, emm76, emm78, emm79, emm81, emm85, emm88, emm90, emm92, emm93,
emm94, emm101, emm102, emm104, emm106, emm108, emm109, emm110, emm112, emm113, emm116, emm118, emm122, emm124, st211,
st221, st587, st809, st854, st1389, st2037, st2147, st2460, st2861UK, st2904, st3757, stD432, stG1750, stNS1033, stXH1. (b) Superantigen pro-
files according to emm types.
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Antimicrobial susceptibility
All GAS strains were susceptible to b-lactams and vancomy-
cin, and had a low-level resistance to gentamicin. The overall
rate of erythromycin resistance was 6.5% (Table 3). How-
ever, a 50% decrease was observed during this 5-year period.
In 2006, 10.9% of GAS strains were erythromycin resistant
whereas the rate was 5% in 2010 (p <0.02). Two emm types,
emm11 and emm28, were over-represented among erythro-
mycin-resistant strains (p <0.001). Among the 100 erythro-
mycin-resistant strains collected during this 5-year period, 71
were constitutively resistant to clindamycin (cMLS), 13 har-
boured an inducible clindamycin-resistant phenotype (iMLS)
and 16 displayed an M phenotype (data not shown). Genetic
characterization of erythromycin and clindamycin resistance
is shown in Table 3. All 16 isolates harbouring an M pheno-
type contained mef(A); among 71 cMLS strains, erm(B) and
erm(A) accounted for 97% (69/71) and 3% (2/71), respec-
tively. Among the 13 iMLS isolates, erm(B) and erm(A)
accounted for 53.8% (7/13) and 46.2% (6/13), respectively. A
significant correlation was observed between erm(B) and
emm11 and emm28 strains (p <0.001 and p <0.02, respec-
tively) and between mef(A) and emm4 strains (p <0.001). The
overall rate of tetracycline resistance was 13% (Table 3). In
contrast to the observed decrease in macrolide resistance,
tetracycline resistance slightly increased and emm11, emm44,
emm77 and emm83 types were strongly associated with this
resistance (p <0.001). Seventy-eight per cent of tetracycline-
resistant strains harboured tet(M). The remaining tetracy-
cline-resistant strains had tet(O) (11.4%), tet(M) + tet(L)(9%),
tet(L) (1%) and tet(M) + tet(K) (0.5%) (Table 3).
Group A streptococcus strains have been tested for fluor-
oquinolone (FQ) resistance since 2008. Among the 614 GAS
strains tested, 82 (13.3%) demonstrated a decrease in FQ
susceptibility (data not shown) and were distributed among
20 different emm types: 66% (10/15) and 45% (5/13) of
emm6 and emm75 strains, respectively.
Discussion
This study describes the clinical and microbiological data
obtained from 1542 cases of invasive GAS infections among
adults in France between 2006 and 2010. The incidence rate
of GAS invasive infection was estimated in 2007 at 3.1 cases
per 100 000 population by the prospective survey conducted
in collaboration with InVS [2]. This rate is comparable to
those recently reported from surveys in Europe (2.1) and
the USA (3.8) [20,21]. Seasonal patterns were observed, but
varied depending upon the year. However, as observed in
other European countries, GAS invasive infections seem to
be more frequent in winter and early spring, which might be
due to the vulnerability of patients with viral respiratory
infections due to syncytial and influenza viruses [20,22].
The median age of patients was 60.3 years and infection
was more frequent in women than in men, as described pre-
viously in Denmark, Norway and Sweden, but this is in con-
trast to what has been observed in other European
countries and the USA [20,21,23,24]. The reasons for the
increasing incidence of GAS invasive infection in the elderly
are not fully understood but it may be explained by the pres-
ence of other comorbidities such as diabetes, a clearly identi-
fied risk factor, especially in GAS skin and soft tissue
infections [20–22]. However, in the age group 40–79 years,
most of the infections occurred in men (p <0.001), especially
with osteoarticular localizations (p <0.02). Women under 60
were more likely to develop intra-abdominal and gynaeco-
obstetrical infections (p <0.001). Among the 340 STSS cases
recorded, the majority was associated with NF (36.5%). The
TABLE 3. Characterization of macrolide and tetracycline-resistant GAS strains according to emm types, France 2006–2010
emm-types
All,
n (%)
Macrolides resistance Tetracycline resistance
Phenotypic pattern Genetic characterization Phenotypic pattern Genetic characterization
Erythromycin
(%)
Clindamycin
(%)
erm(A)
(%)
erm(B)
(%)
mef(A)
(%)
Tetracycline
(%)
tet(M)
(%)
tet(O)
(%)
tet(L)
(%)
tet(M) +
tet(L) (%)
tet(M) +
tet(K) (%)
emm1 373 (24.2) 1 (0.3) 1 (0.3) 0 (0) 1 (100) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0)
emm4 82 (5.3) 6 (7.3) 0 (0) 0 (0) 0 (0) 6 (100) 1 (1.2) 1 (0.5) 0 (0) 0 (0) 0 (0) 0 (0)
emm11 40 (2.6) 22 (55) 21 (52.5) 0 (0) 21 (95) 1 (5) 24 (60) 21 (10.5) 0 (0) 1 (0.5) 1 (0.5) 1 (0.5)
emm12 77 (5) 5 (6.5) 1 (1.3) 1 (20) 0 (0) 4 (80) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0)
emm22 18 (1.2) 3 (16.7) 3 (16.7) 0 (0) 3 (100) 0 (0) 9 (50) 9 (4.5) 0 (0) 0 (0) 0 (0) 0 (0)
emm28 267 (17.3) 42 (15.7) 42 (15.7) 0 (0) 42 (100) 0 (0) 1 (0.4) 1 (0.5) 0 (0) 0 (0) 0 (0) 0 (0)
emm44 17 (1.1) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 15 (88.2) 13 (6.5) 0 (0) 0 (0) 2 (1) 0 (0)
emm64 11 (0.7) 1 (9.1) 1 (9.1) 1 (100) 0 (0) 0 (0) 9 (81.8) 9 (4.5) 0 (0) 0 (0) 0 (0) 0 (0)
emm75 42 (2.7) 3 (7.1) 1 (2.4) 1 (33) 0 (0) 2 (66) 3 (7.1) 1 (0.5) 1 (0.5) 0 (0) 1 (0.5) 0 (0)
emm77 36 (2.3) 2 (5.6) 2 (5.6) 2 (100) 0 (0) 0 (0) 2 (75) 6 (3) 21 (10.5) 0 (0) 0 (0) 0 (0)
emm82 14 (0.9) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 5 (35.7) 5 (2.5) 0 (0) 0 (0) 0 (0) 0 (0)
emm83 15 (1.0) 2 (13.3) 2 (13.3) 0 (0) 2 (2) 0 (0) 12 (80) 12 (6) 0 (0) 0 (0) 0 (0) 0 (0)
emm89 228 (14.8) 2 (0.9) 2 (0.9) 1 (1) 1 (1) 0 (0) 1 (0.4) 0 (0) 1 (0.5) 0 (0) 0 (0) 0 (0)
Others 162 11 (6.8) 8 (4.9) 2 (2) 6 (6) 3 (3) 94 (58) 79 (39.5) 0 (0) 1 (0.5) 14 (7) 0 (0)
Total 1542 100 (6.5) 84 (5.4) 8 (8) 76 (76) 16 (16) 201 (13) 157 (78.1) 23 (11.4) 2 (1) 18 (9) 1 (0.5)
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fatality rate among those STSS cases was 44.9%, a value con-
sistent with the 43% reported in 2007 [2].
emm1 was the most prevalent emm type, which is in
accordance with results from the USA, Japan and across Eur-
ope, followed by emm28 and emm89 [25–27]. However, we
observed that emm1 decreased since 2006, to be replaced
by emm28, emm89 and emm3 types (Fig. 2a). In 2010, emm1
represented only 13.2% of the strains compared with 24.9%
and 13.6% for emm28 and emm89, respectively. Fluctuations
of emm types have been observed in other European coun-
tries and they may reflect ongoing epidemic waves, herd
immunity or population immunity [20,27].
As observed in previous surveys, emm1 was associated
with NF and emm28 with puerperal infections [20]. Addition-
ally, this study highlights a correlation between emm28 and
erysipelas. Therefore, the fluctuation observed for emm1 and
emm28 is likely to be due to a combination of several factors
over the 5-year period: the increase of gynaeco-obstetrical
sepsis from 4.9 to 9.8%, the increase of erysipelas from 8.2
to 13.6%, and the decrease of NF from 25.7 to 19.2%.
As already reported, speA was detected in almost all emm1
(98%) and emm3 (99%) types and less frequently among other
emm types. speC was detected in more than 90% of emm2,
emm4, emm6, emm11 and emm28. The ssa gene was detected
in more than 70% of emm3, emm4, emm22 and emm87. Nev-
ertheless, most of the strains within a given emm type shared
the same SA gene profile, which is that found in other coun-
tries [27,28]. The relevance of SA genes relating to invasive
infections remains controversial as they are present at the
same rate in non-invasive isolates [23].
Up to now, GAS remained universally susceptible to
b-lactams and glycopeptides. All strains tested were suscep-
tible to penicillin, amoxicillin and vancomycin, whereas
resistances were observed for macrolides and tetracycline.
The increase of macrolide and lincosamide resistance rates
among GAS observed in many countries constitutes a
major concern because these antibiotics are recommended
for the treatment of GAS infections in penicillin-allergic
patients and in case of STSS. In France, a marked increase
was observed in 2004 with a rate reaching 35% [10,29]. In
this study, we show that since 2006, erythromycin resis-
tance decreased significantly from 10.9 to 5% (p <0.02), an
evolution already observed in Spain and Portugal [30–32].
The reason for this decrease is likely to be due to the
reduction of macrolides prescription in France since 2002
[33]. Macrolide resistance was mainly due to the presence
of erm(B) (76%) among emm28 and emm11 types (Table 3),
as reported in other European countries [30,32,34]. Sur-
prisingly, emm1 strains accounting for the majority of STSS
and NF are rarely resistant to erythromycin (0.3%). Among
mef(A)-carrying isolates the predominant clone was emm4,
which is widespread in Europe [10,19,34–36]. The overall
rate of tetracycline resistance reached 13% (Table 3). The
prevalence of tetracycline-resistant strains fluctuates over
the study period, between 11 and 16.6% (Table 3). tet(M)
accounted for 78.6% of resistant strains and emm77 was
the most prevalent emm type (13.4%) among tetracycline-
resistant strains, as described in Germany [37]. However,
emm11, emm44 and emm83 strains were also strongly asso-
ciated with tetracycline resistance. Finally, non-susceptible
FQ strains were due to the emergence of an emm6 clone,
as described in Spain [38,39].
In conclusion, this study provides accurate data about the
current epidemiological situation regarding adult invasive
GAS infections in France. emm1 still remains the most preva-
lent emm type and is associated with the most life-threaten-
ing clinical manifestations. Fortunately, emm1 strains remain
susceptible to all anti-streptococcal antibiotics. Importantly,
the trend observed in 2007 concerning the decrease of
erythromycin resistance was confirmed in 2008–2010, an
evolution that can be correlated with the improvement of
good practices in antibiotic use [33].
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